BioWorld Asia

Sep. 19, 2007

NeuroSearch Shares Boosted By Tesofensine Obesity Data

Shares in NeuroSearch A/S gained almost 22 percent Monday on news that its candidate obesity drug tesofensine attained an average weight reduction of about 10 ten percent in a Phase IIb clinical trial. (BioWorld International) Read More

Ganymed Adds To Series C; Closes 37.2M Financing Round

No Abstract Read More

Gene Expression Levels Vary At Higher Levels Than Thought

Oxford BioMedica Using Sanofi Deal As Catalyst For Growth

European Industry Seeks Wider Links In Orphan Drug Programs

Other News To Note

Renovo Reports Positive Data From Phase IIb Trial Of Juvista

Mutabilis, Oroxcell Collaborate On Preclinical Antibiotic Agent

EU Commissioner Defends Rule Banning GM-Free Zones

Today's news in brief

BioWorld

BioWorld briefs for June 29, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 30, 2026

Illustration demonstrating gut-brain axis

CINP 2026: Gut microbiota could predict antidepressant response

BioWorld

The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...

Ascending BCI systems deepen national security, ethical concerns

BioWorld

Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...

Handshake, businessmen holding dollar sign, lightbulb

Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal

BioWorld

A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...